D-Serine.

D-serine is made in the body by serine racemase acting on L-serine, so L-serine intake feeds the endogenous D-serine pool. L-serine is the substrate side of the same reaction rather than a second, separate input.

Serine racemase is a pyridoxal 5-phosphate enzyme, so vitamin B6 status governs how fast L-serine is converted to D-serine. Low B6 limits that conversion regardless of how much substrate is present.

Glycine and D-serine are the two endogenous co-agonists at the same glycine site of the NMDA receptor, so they occupy one binding pocket rather than adding to each other. D-serine is the dominant co-agonist at forebrain synapses, so stacking the two is largely redundant.

Magnesium sits in the NMDA channel pore as a voltage-dependent block, while D-serine occupies the co-agonist site that permits opening. The two act on the same receptor in opposite directions, which is worth stating rather than framing as an additive stack.

Zinc binds a modulatory site on the NMDA receptor complex and damps channel opening, working in the opposite direction from D-serine at the co-agonist site. The two act on the same receptor from different sites.

Glutamine is the precursor of the glutamate that occupies the agonist site of the NMDA receptor, while D-serine occupies the co-agonist site. Both signals must be present for the channel to open.

Folate-dependent one-carbon transfer keeps the glycine and serine pool in balance, and L-serine is the substrate serine racemase converts to D-serine. Folate status therefore feeds the upstream supply.

D-serine is broken down by D-amino acid oxidase, a flavoenzyme that carries FAD as its prosthetic group. Riboflavin is the dietary precursor of FAD, so riboflavin status sits upstream of how quickly D-serine is cleared in tissues where that enzyme is expressed. This is a settled cofactor relationship rather than a tested combination, and it describes turnover, not an outcome.

The body makes serine from the glycolytic intermediate 3-phosphoglycerate, and the first committed step runs through phosphoglycerate dehydrogenase, which requires NAD+ as its electron acceptor. Niacin is the precursor of NAD+, so niacin status sits underneath endogenous serine supply. D-serine itself comes from L-serine by racemisation, which puts this two steps upstream.

Serine hydroxymethyltransferase moves a one-carbon unit from L-serine onto tetrahydrofolate, producing glycine and 5,10-methylene-THF. The reaction runs in both directions, so folate status and serine availability shape each other. Supplemental D-serine does not enter this reaction directly; it interacts with it through the shared L-serine pool.

Methionine synthase needs vitamin B12 to hand the methyl group from 5-methyl-THF to homocysteine. When that step slows, folate accumulates in the methyl form and the serine-to-glycine reaction that feeds it backs up. The link to D-serine is indirect and runs through the L-serine pool that supplies the racemase.

L-serine condenses with homocysteine through cystathionine beta-synthase to form cystathionine, which is then cleaved to cysteine. Serine is therefore a direct structural contributor to cysteine synthesis in humans. Anyone dosing D-serine is also loading a pool that partly interconverts with L-serine, which is where the connection sits.

The serine head group of phosphatidylserine comes from free L-serine by base exchange with phosphatidylethanolamine or phosphatidylcholine. Serine is also the starting substrate for sphingolipid synthesis, where it condenses with palmitoyl-CoA. Supplemental phosphatidylserine and supplemental serine therefore meet in the same membrane lipid economy, though only the L form enters it.

D-serine occupies the glycine co-agonist site on the NMDA receptor. Sarcosine works on the same site from a different angle, by inhibiting the GlyT1 transporter so synaptic glycine rises. Because both converge on occupancy of one site, their effects are not simply additive, and this describes receptor signalling rather than any clinical result.

L-theanine is a glutamate analogue with weak affinity at ionotropic glutamate receptors and is commonly taken for calm focus. D-serine acts as the co-agonist that gates NMDA receptor opening. The two touch the same signalling system from opposite ends, and no combination trial in people was identified.

Taurine is a weak agonist at glycine and GABA-A receptors, so it shifts the balance of inhibitory tone in the same circuits where NMDA receptors sit. D-serine pushes the excitatory side of that balance by co-activating NMDA receptors. The interaction is plausible from receptor pharmacology and has not been measured together in people.

NAC supplies cysteine and also loads the cystine-glutamate antiporter, which raises extrasynaptic glutamate and changes tone at glutamate receptors. D-serine acts at the co-agonist site of one of those receptors. The overlap is mechanistic and untested as a pair in humans.